Schor Chen 4

What Happened
Schor Chen, a director of Karyopharm Therapeutics Inc., was granted 15,508 restricted stock units (RSUs) on May 21, 2026. The award is reported at an acquisition price of $0.00 (transaction code A), meaning no cash was paid. The RSUs convert one-for-one into Karyopharm common shares upon settlement; they vest 100% on May 21, 2027 but actual delivery of shares is deferred until the earlier of the director’s separation from service or a change-in-control.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (appears timely under the SEC’s two-business-day rule).
• Grant: 15,508 RSUs @ $0.00 (Award, code A).
• Vesting/settlement: 100% vests on May 21, 2027; delivery deferred until separation or change-in-control (per footnote).
• Plan: Granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
• Shares owned after transaction: Not specified in the filing.
• Filing accession: 0001340875-26-000005.

Context
RSU awards are compensatory grants that convert to shares on settlement; they do not represent immediate open‑market purchases or sales. Such awards are routine for directors and executives and do not, by themselves, indicate buy/sell sentiment—purchases tend to be a clearer bullish signal for retail investors.